Biomarkers to Enhance Early Schizophrenia Treatment

Part of paid clinical trials in La Jolla, California.

Sponsor
Northwell Health
Study ID
NCT06969755
Phase
PHASE4
Status
Recruiting
Apply to this trial

Conditions

  • Schizophenia Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - 35 Years
Healthy Volunteers
Not accepted

Interventions

  • aripiprazole — DRUG
    aripiprazole arm (titrated dose)
  • risperidone — DRUG
    risperidone arm (titrated dose)
  • clozapine — DRUG
    clozapine (titrated dose)

Study Details

This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.

Key Dates

Start date
Sep 30, 2025
Status verified
May 2026
Primary completion
Jul 30, 2030
Completion
Jul 30, 2030

Study Design

Enrollment
180 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: risperidone
    risperidone treatment provided per protocol
  • Active Comparator: aripiprazole
    aripiprazole treatment per protocol
  • Active Comparator: clozapine
    clozapine treatment per protocol

Primary Outcome Measure

Total change in BPRS Symptoms [ Time Frame: 12 weeks ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
University of California San DiegoLa JollaCalifornia92093
Cherine Akkarine
[email protected]
909-589-4678
McLeanBelmontMassachusetts02478
Dost Ongur
[email protected]
617-855-3922
Feinstein Institute for Medical ResearchGlen OaksNew York11004
Taylor Marzouk Coordinator
[email protected]
718-470-8905

Find similar trials in La Jolla, CA

By research site
University of California San Diego· La Jolla, CAMcLean· Belmont, MAFeinstein Institute for Medical Research· Glen Oaks, NY

Related Studies